Insilico Medicine
Generative AI platform for end-to-end drug discovery, from target identification to clinical trials
Enterprise·Technical·Powered by Insilico Medicine (proprietary LLLMs)·API available
Key strengths
End-to-end AI-driven drug discovery pipeline (target ID to clinical trials)Generative chemistry and biology AI (Chemistry42, Generative Biologics)Large Language of Life Models (LLLMs) for biomedical researchValidated therapeutic pipeline with programs in Phase I/II trialsMulti-modal platform covering disease modeling, molecule generation, and clinical prediction
Enterprise pricing
Cambridge, USA
Founded 2014
No ratings yet
- Multi-omics target identification: Use PandaOmics to integrate transcriptomics, proteomics, and genomics datasets to rank and validate novel therapeutic targets for a given disease.
- Generative small molecule design: Deploy Chemistry42 to generate, score, and optimize lead compounds against specified targets using reinforcement learning pipelines.
- Biologic sequence design: Apply Generative Biologics to produce antibody or protein therapeutic candidates with desired binding and stability properties.
- Clinical trial outcome prediction: Feed trial design parameters and historical data into inClinico to estimate Phase II/III success probabilities and optimize trial design.
- Biomedical literature mining & hypothesis generation: Integrate Science42:DORA (LLM assistant) into research workflows to automate literature review, extract mechanistic insights, and draft scientific hypotheses.
- AI benchmarking & model evaluation: Use MMAI Gym and Insilico Bench to benchmark internal or third-party ML models against standardized drug discovery tasks and published Insilico baselines.